AZD3632 + posaconazole

AZD3632 + posaconazole is a combination of AZD3632, an investigational small molecule, and posaconazole, an approved triazole antifungal. This combination is being studied in advanced hematologic malignancies (including acute myeloid leukemia, acute lymphoblastic leukemia, and higher-risk myelodysplastic syndromes) with genotypes such as KMT2A rearrangement and NPM1 mutation associated with HOX gene overexpression. AZD3632’s specific mechanism of action is not publicly disclosed, but it is under investigation for its anticancer properties in these genetic contexts, while posaconazole serves to prevent or treat invasive fungal infections commonly occurring in immunocompromised leukemia patients[1][3][5][7].